Objective To study the longterm result of endocrinotherapy and (or) radiotherapy for moderately and far advanced prostate cancer. Methods 256 cases of moderately or far advanced prostate cancer were treated with endocrinotherapy (surgical castration + postoperative drug administration) and (or) radiotherapy.182 cases were of stage C and 74 stage D.There were 236 adenocarcinoma,7 squamous cancer and 13 undifferentiated cancer.Gleason score was ≥6 in 202 patients and 134 had pelvic lymphoid metastasis. Results In 92.2%of the patients,the serum PSA dropped under 2 ng/ml shortly after the treatment.The overall 5,10,15 year survival rates were 48.8%,29.7% and 13.3% respectively.For stage C cases,these were 58.2%,38.4%,17.7% and for stage D 25.7%,6.4%,0.The 5 and 10 year survival rates were significantly different between stage C and D(P

Objective To investigate the clinical and laboratory diagnosis of adult hemophagocytic syn-drome (HPS) . Methods Clinical data of 24 patients with HPS from 2000 to 2008 were retrospectively analyzed. Results Of the 24 HPS cases, 12 had a malignant associated hemophagocytic syndrome (MHAS), and 10 were fi-nally diagnosed by bone marrow immunohistochemist ;Of 12 cases in non-MAHS group,4 were with virus associated hemophagocytic syndrome (VAHS), and 4 were of the other infections, whereas 4 patients diagnosed of immune associated HS (MAS). There were significant difference in onset age, mortality, serum lactate dehydrogenase (LDH) and serum ferritin(FER) and neutrophilic NAP between non-MAHS group and MAHS group(P <0.01 ,P<0.05). In all cases bone marrow biopsy showed significant differences in cytological and pathological features between MAHS group and non-MAHS group. Conclusion Etiology,immunology,and bone marrow cell biopsy and pathology as well contribute to the diagnosis and typing of HPS and will give a guide to the therapy.

Objective:To investigate the diagnostic value of peripheral blood systemic immune inflammatory in-dex(SII)in histological chorioamnionitis(HCA)and the predictive value of adverse pregnancy outcomes.Meth-ods:A total of 138 pregnant women with suspected HCA were included from January 2021 to June 2022 in Peo-ple's Hospital of Zhengzhou as the research objects.According to the results of placental pathology examination,they were divided into non-HCA group(66 cases)and HCA group(72 cases).The general clinical data,laboratory indicators and adverse outcome indicators of the two groups were compared,and the relationship between the a-bove indicators and HCA was analyzed by multivariate Logistic regression.ROC curve was used to analyze the predictive value of SII for HCA and adverse pregnancy outcomes.Results:①Logistic regression analysis showed that increased neutrophil percentage(Neut％)and SII could increase the risk of HCA(OR＞1,P＜0.05),and in-creased lymphocyte percentage(Lym％)was beneficial for reducing the risk of HCA(OR＜1,P＜0.05).②ROC curve analysis showed that the area under the curve(AUC)of Neut％and Lym％for diagnosing HCA were 0.628 and 0.638,respectively,while the AUC of SII was higher(0.722),and the diagnostic threshold of SII was 974.49 ×109/L.③The rates of postpartum hemorrhage,neonatal infection and premature delivery in high SII group(SII＞974.49 ×103/L)were higher than those in low SII group(SII ≤974.49 ×109/L),and the difference was statistically significant(P＜0.05).The value of SII in predicting postpartum hemorrhage(AUC 0.708)and neonatal infection(AUC 0.848)were higher than that in preterm birth(AUC 0.637).Conclusions:Abnormal Neut％and Lym％levels increase the risk of HCA to some extent,but the diagnostic value of HCA is average.Peripheral blood SII has high diagnostic value in HCA,and has good predictive value for postpartum hemorrhage and neonatal infection,which is expected to be a new indicator for prenatal diagnosis and prognosis prediction of adverse pregnancy outcomes in HCA.

At present,China has issued a series of standards relating to traditional Chinese medicine(TCM). The standard system has already taken shape,but there are still some problems,such as incomplete standard system,low standard quality,inadequate application,insufficient study strength and lack of talent. This paper makes a detailed analysis of current management and development of standardization of traditional Chinese medicine in the aspects of " management mechanism and system construction" and " standards".The problems existing in the standardization of TCM are analyzed in three aspects: quality and popularization,standard research and talent reserve. At the same time,some suggestions are put forward to solve the problems. First,we shall strengthen the management of top-level design; second,we shall guide the transformation of high-quality scientific and technological achievements to standards;third,we shall consolidate the basic research of standardization of TCM; fourth,we shall focus on cultivating standardized technical talents; and fifth,we shall strengthen the standard research and development work in key fields.
China ; Drug Delivery Systems ; Drugs, Chinese Herbal ; Medicine, Chinese Traditional ; Reference Standards